EZGİ EDA ERDEN, ÖZLEM OYARDİ
The Journal of European Internal Medicine Professionals - 2025;3(1):41-46
Human papillomavirus (HPV) is a double-stranded DNA virus from the Papillomaviridae family that primarily infects basal epithelial cells. This virus is responsible for causing warts, papillomas, and various cancers in both men and women. To date, over 200 HPV types have been identified, which are classified into high-risk and low-risk categories. High-risk types, such as HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 are known to contribute significantly to cancer development. Among these, HPV 16 and 18 are the most common and are strongly associated with the onset of cancer. HPV remains a significant global public health issue, posing substantial social and economic burdens. Despite extensive research, there is currently no approved or proven drug for the effective treatment of HPV infections. However, vaccines play a critical role in the prevention of HPV-related diseases. The U.S. Food and Drug Administration (FDA) has approved three vaccines that provide protection against high-risk HPV types. These vaccines have led to a marked reduction in HPV incidence and associated complications. The World Health Organization (WHO) strongly recommends HPV vaccination as a preventive measure. Furthermore, ongoing research aims to develop next-generation vaccines to enhance protection against HPV. This study underscores the importance of HPV vaccines and highlights their role in mitigating the impact of this pervasive virus.
